Junna Oba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Junna Oba has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Takeru Abe
Center for Integrated Sciences and Humanities Fukushima Medical University Fukushima Japan
3 shared publications Yoichi Moroi
3 shared publicationsAkihito Hagihara
2 shared publicationsMasutaka Furue
2 shared publicationsTakeshi Nakahara
2 shared publicationsA. Hagihara
Department of Dermatology and *Health Services Management and Policy, Graduate School of Medical Sciences, Kyushu University, 3‐1‐1 Maidashi, Higashi‐ku, Fukuoka 812‐8582, Japan
1 shared publication
Latest Publications
- 1 December 2011
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 65 (6) , 1152-1160
Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma
- 1 December 2011
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 65 (6) , 1152-1160
Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma
- 28 July 2011
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 165 (3) , 506-512
Expression of milk fat globule epidermal growth factor-VIII may be an indicator of poor prognosis in malignant melanoma
Milk fat globule epidermal growth factor-VIII (MFG-E8) is a secreted protein that binds phosphatidylserine and promotes apoptotic cell ingestion by phagocytes, mediating the immune tolerance and maintenance of homeostasis. A recent study has shown that MFG-E8 expression in human melanoma is increased with tumour progression; however, the effect of its expression on patient survival has not yet been clarified. To analyse MFG-E8 expression in melanoma, and to determine whether it can serve as a marker for diagnosis, tumour progression and/or prognosis. MFG-E8 expression was examined by immunohistochemistry in 60 primary melanomas, 22 metastatic lesions and 30 benign naevi. The following clinicopathological variables were evaluated: age, gender, histological type, tumour site, Breslow thickness, Clark's level, the presence or absence of ulceration and tumour-infiltrating lymphocytes, and survival periods. Statistical analyses were performed to assess associations and melanoma-specific survival. MFG-E8 expression was significantly higher in primary and metastatic melanoma than in naevus. Furthermore, it increased according to tumour progression and metastasis. Patients with MFG-E8 expression in primary tumours had significantly shorter survival periods than those without MFG-E8 expression. Univariate and multivariate analyses revealed that MFG-E8 expression was a statistically significant and independent prognostic factor. MFG-E8 expression may serve as a tumour progression marker and can predict an unfavourable prognosis in patients with melanoma.
- 28 July 2011
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 165 (3) , 506-512
Expression of milk fat globule epidermal growth factor-VIII may be an indicator of poor prognosis in malignant melanoma
Milk fat globule epidermal growth factor-VIII (MFG-E8) is a secreted protein that binds phosphatidylserine and promotes apoptotic cell ingestion by phagocytes, mediating the immune tolerance and maintenance of homeostasis. A recent study has shown that MFG-E8 expression in human melanoma is increased with tumour progression; however, the effect of its expression on patient survival has not yet been clarified. To analyse MFG-E8 expression in melanoma, and to determine whether it can serve as a marker for diagnosis, tumour progression and/or prognosis. MFG-E8 expression was examined by immunohistochemistry in 60 primary melanomas, 22 metastatic lesions and 30 benign naevi. The following clinicopathological variables were evaluated: age, gender, histological type, tumour site, Breslow thickness, Clark's level, the presence or absence of ulceration and tumour-infiltrating lymphocytes, and survival periods. Statistical analyses were performed to assess associations and melanoma-specific survival. MFG-E8 expression was significantly higher in primary and metastatic melanoma than in naevus. Furthermore, it increased according to tumour progression and metastasis. Patients with MFG-E8 expression in primary tumours had significantly shorter survival periods than those without MFG-E8 expression. Univariate and multivariate analyses revealed that MFG-E8 expression was a statistically significant and independent prognostic factor. MFG-E8 expression may serve as a tumour progression marker and can predict an unfavourable prognosis in patients with melanoma.
- 1 May 2011
- Published by Elsevier in Journal of Dermatological Science
- Vol. 62 (2) , 116-123
Expression of c-Kit, p-ERK and cyclin D1 in malignant melanoma: An immunohistochemical study and analysis of prognostic value
- 1 May 2011
- Published by Elsevier in Journal of Dermatological Science
- Vol. 62 (2) , 116-123
Expression of c-Kit, p-ERK and cyclin D1 in malignant melanoma: An immunohistochemical study and analysis of prognostic value
- 25 October 2007
- Published by Wiley in The Journal of Dermatology
- Vol. 34 (11) , 782-785
Case of adult T‐cell leukemia/lymphoma manifesting marked purpura
We present a case of a 62-year-old woman with marked purpura, first appearing on both legs, then spreading over the whole body, including the face. At presentation, the patient was thought to have Henoch-Schonlein purpura. However, a skin biopsy from a purpuric lesion revealed prominent infiltrations of atypical lymphocytes into the papillary dermis and marked extravasation of erythrocytes through the epidermis and upper dermis. Antibody to human T-lymphotropic virus type 1 (HTLV-1) was present in the serum and samples from skin lesions revealed HTLV-1 proviral DNA integration, as well as a clonal T-cell receptor Cbeta1 gene rearrangement. We therefore diagnosed this case as adult T-cell leukemia/lymphoma (ATL), and the purpuric lesions as ATL-specific. Soon after the initiation of chemotherapy, these purpuric lesions began to resolve with pigmentation.
- 25 October 2007
- Published by Wiley in The Journal of Dermatology
- Vol. 34 (11) , 782-785
Case of adult T‐cell leukemia/lymphoma manifesting marked purpura
We present a case of a 62-year-old woman with marked purpura, first appearing on both legs, then spreading over the whole body, including the face. At presentation, the patient was thought to have Henoch-Schonlein purpura. However, a skin biopsy from a purpuric lesion revealed prominent infiltrations of atypical lymphocytes into the papillary dermis and marked extravasation of erythrocytes through the epidermis and upper dermis. Antibody to human T-lymphotropic virus type 1 (HTLV-1) was present in the serum and samples from skin lesions revealed HTLV-1 proviral DNA integration, as well as a clonal T-cell receptor Cbeta1 gene rearrangement. We therefore diagnosed this case as adult T-cell leukemia/lymphoma (ATL), and the purpuric lesions as ATL-specific. Soon after the initiation of chemotherapy, these purpuric lesions began to resolve with pigmentation.